Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies.

Çakmak-Görür N, Radke J, Rhein S, Schumann E, Willimsky G, Heppner FL, Blankenstein T, Pezzutto A.

Leukemia. 2019 Apr;33(4):1039-1043. doi: 10.1038/s41375-018-0330-7. Epub 2019 Jan 3. No abstract available.

2.

Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.

Weber ANR, Cardona Gloria Y, Çınar Ö, Reinhardt HC, Pezzutto A, Wolz OO.

Cancer Immunol Immunother. 2018 Nov;67(11):1797-1807. doi: 10.1007/s00262-018-2242-9. Epub 2018 Sep 11. Review.

PMID:
30203262
3.

[Extra-hepatic manifestations associated with Hepatitis and virus infection].

Piscitani L, Longo MO, Grabocka X, Silvestri S, Arazzi M, Pezzutto A, Micioni G, Di Fulvio G, Di Pietro LO, Schiazza A, Di Vito R, Bonomini M.

G Ital Nefrol. 2018 Mar;35(2). pii: 2018-vol2. Italian.

PMID:
29582966
4.

[Therapy of glucocorticoid induced osteoporosis].

Arazzi M, Di Fulvio G, Di Pietro LO, Grabocka X, Longo MO, Micioni G, Pezzutto A, Piscitani L, Schiazza A, Silvestri S, Vigilante G, Amoroso L, Bonomini M.

G Ital Nefrol. 2017 Dec 5;34(Nov-Dec). pii: 2017-vol6. Review. Italian.

PMID:
29207221
5.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

6.

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, Pezzutto A, Bondarenko I, Stewart DA, Shnaidman M, Sullivan S, Vandendries E, Tobinai K, Ramchandren R, Hamlin PA, Giné E, Ando K.

Br J Haematol. 2018 Aug;182(4):583-586. doi: 10.1111/bjh.14820. Epub 2017 Jul 5. No abstract available.

7.

Confocal endomicroscopy in diagnosis of intestinal chronic graft-versus-host disease.

Rieger K, Günther U, Erben U, Kühl A, Loddenkemper C, Pezzutto A, Siegmund B, Bojarski C.

Hematol Oncol. 2018 Feb;36(1):291-298. doi: 10.1002/hon.2446. Epub 2017 May 25.

PMID:
28547857
8.

[Severe neutropenia during treatment with amoxicillin/clavulanic acid in a patient on regular hemodialysis treatment].

Spetrino N, Arazzi M, Di Fulvio G, Giunta F, Grabocka X, Longo MO, Micioni G, Pezzutto A, Silvestri S, Tondo M, Vigilante G, Bonomini M.

G Ital Nefrol. 2016 Nov-Dec;33(6). pii: gin/33.6.7. Italian.

PMID:
28134402
9.

CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model.

Nguyen-Hoai T, Pham-Duc M, Gries M, Dörken B, Pezzutto A, Westermann J.

Cancer Gene Ther. 2016 Jun;23(6):162-7. doi: 10.1038/cgt.2016.9. Epub 2016 Apr 8.

PMID:
27056671
10.

Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223.

Berenstein R, Nogai A, Waechter M, Blau O, Kuehnel A, Schmidt-Hieber M, Kunitz A, Pezzutto A, Dörken B, Blau IW.

Mol Carcinog. 2016 Dec;55(12):1927-1939. doi: 10.1002/mc.22440. Epub 2015 Nov 24.

PMID:
27023728
11.

Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma.

Korfel A, Schlegel U, Herrlinger U, Dreyling M, Schmidt C, von Baumgarten L, Pezzutto A, Grobosch T, Kebir S, Thiel E, Martus P, Kiewe P.

J Clin Oncol. 2016 May 20;34(15):1757-63. doi: 10.1200/JCO.2015.64.9897. Epub 2016 Mar 14.

PMID:
26976424
12.

DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties.

Flörcken A, Kopp J, Kölsch U, Meisel C, Dörken B, Pezzutto A, Westermann J.

Hum Vaccin Immunother. 2016 May 3;12(5):1117-23. doi: 10.1080/21645515.2015.1132965. Epub 2016 Feb 10.

13.

Myeloid-derived suppressor cells in human peripheral blood: Optimized quantification in healthy donors and patients with metastatic renal cell carcinoma.

Flörcken A, Takvorian A, Singh A, Gerhardt A, Ostendorf BN, Dörken B, Pezzutto A, Westermann J.

Immunol Lett. 2015 Dec;168(2):260-7. doi: 10.1016/j.imlet.2015.10.001. Epub 2015 Oct 14.

PMID:
26462434
14.

Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.

Ferrero S, Pastore A, Scholz CW, Forstpointner R, Pezzutto A, Bergmann L, Trümper L, Finke J, Keller U, Ghione P, Passera R, Hiddemann W, Weigert O, Unterhalt M, Dreyling M.

Leukemia. 2016 Apr;30(4):984-7. doi: 10.1038/leu.2015.215. Epub 2015 Aug 5. No abstract available.

PMID:
26242461
15.

Gene Gun Her2/neu DNA Vaccination: Evaluation of Vaccine Efficacy in a Syngeneic Her2/neu Mouse Tumor Model.

Nguyen-Hoai T, Pezzutto A, Westermann J.

Methods Mol Biol. 2015;1317:17-37. doi: 10.1007/978-1-4939-2727-2_2.

PMID:
26072399
16.

Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia.

Schneider T, Flörcken A, Singh A, Türkmen S, Burmeister T, Anagnostopoulos I, Pezzutto A, Dörken B, Westermann J.

Ann Hematol. 2015 Aug;94(8):1337-45. doi: 10.1007/s00277-015-2400-5. Epub 2015 May 22.

PMID:
25994787
17.

Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.

Berenstein R, Blau IW, Suckert N, Baldus C, Pezzutto A, Dörken B, Blau O.

J Exp Clin Cancer Res. 2015 May 22;34:55. doi: 10.1186/s13046-015-0173-2.

18.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Müller MC; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group.

Blood. 2015 Jul 2;126(1):42-9. doi: 10.1182/blood-2015-01-617993. Epub 2015 Apr 27.

19.

Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region.

Berenstein R, Blau O, Nogai A, Waechter M, Slonova E, Schmidt-Hieber M, Kunitz A, Pezzutto A, Doerken B, Blau IW.

BMC Cancer. 2015 Feb 18;15:68. doi: 10.1186/s12885-015-1078-3.

20.

Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.

Lerch K, Meyer AH, Stroux A, Hirt C, Keller U, Viardot A, Marks R, Schreiber S, Pezzutto A, Scholz CW.

Ann Hematol. 2015 Jun;94(6):981-8. doi: 10.1007/s00277-015-2303-5. Epub 2015 Feb 3.

PMID:
25645656
21.

Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB.

Flörcken A, Grau M, Wolf A, Weilemann A, Kopp J, Dörken B, Blankenstein T, Pezzutto A, Lenz P, Lenz G, Westermann J.

Int J Cancer. 2015 Apr 15;136(8):1814-26. doi: 10.1002/ijc.29230. Epub 2014 Sep 30.

22.

R-split-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma.

Kreher S, Lammer F, Augustin D, Pezzutto A, Baldus CD.

Eur J Haematol. 2014 Jul;93(1):70-6. doi: 10.1111/ejh.12304. Epub 2014 Mar 28.

PMID:
24612334
23.

Long-term structured follow-up is essential after curative cancer treatment.

Keilholz U, Pezzutto A, Budach V, Eggert A.

Dtsch Arztebl Int. 2014 Jan 6;111(1-2):1-2. doi: 10.3238/arztebl.2014.0001. No abstract available.

24.

Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer.

Jehn CF, Böning L, Kröning H, Pezzutto A, Lüftner D.

Eur J Cancer. 2014 May;50(7):1269-75. doi: 10.1016/j.ejca.2014.01.005. Epub 2014 Feb 3.

PMID:
24503027
25.

Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.

Meyer AH, Stroux A, Lerch K, Eucker J, Eitle J, Hohloch K, Andrzejak M, Possinger K, Dörken B, Pezzutto A, Scholz CW.

Ann Oncol. 2014 Jan;25(1):210-5. doi: 10.1093/annonc/mdt507.

PMID:
24356632
26.

Improvement of paraneoplastic limbic encephalitis after systemic treatment with rituximab in a patient with B-cell chronic lymphocytic leukemia.

Nogai H, Israel-Willner H, Zschenderlein R, Pezzutto A.

Case Rep Hematol. 2013;2013:958704. doi: 10.1155/2013/958704. Epub 2013 Aug 1.

27.

Peripheral blood sCD3⁻ CD4⁺ T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma.

Singh A, Schabath R, Ratei R, Stroux A, Klemke CD, Nebe T, Flörcken A, van Lessen A, Anagnostopoulos I, Dörken B, Ludwig WD, Pezzutto A, Westermann J.

Hematol Oncol. 2014 Mar;32(1):16-21. doi: 10.1002/hon.2080. Epub 2013 Jun 24.

PMID:
23798351
28.

Anti-leukemia T cells in AML: TNF-α⁺ CD8⁺ T cells may escape detection and possibly reflect a stage of functional impairment.

Flörcken A, van Lessen A, Terwey TH, Dörken B, Arnold R, Pezzutto A, Westermann J.

Hum Vaccin Immunother. 2013 Jun;9(6):1200-4. doi: 10.4161/hv.24250. Epub 2013 Apr 8.

29.

Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.

Flörcken A, Kopp J, van Lessen A, Movassaghi K, Takvorian A, Jöhrens K, Möbs M, Schönemann C, Sawitzki B, Egerer K, Dörken B, Pezzutto A, Westermann J.

Hum Vaccin Immunother. 2013 Jun;9(6):1217-27. doi: 10.4161/hv.24149. Epub 2013 Mar 4.

30.

High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination.

Pohla H, Buchner A, Stadlbauer B, Frankenberger B, Stevanovic S, Walter S, Frank R, Schwachula T, Olek S, Kopp J, Willimsky G, Stief CG, Hofstetter A, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ.

Mol Med. 2013 Feb 8;18:1499-508. doi: 10.2119/molmed.2012.00221.

31.

HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: Gene gun is superior to jet injector in inducing CTL responses and protective immunity.

Nguyen-Hoai T, Kobelt D, Hohn O, Vu MD, Schlag PM, Dörken B, Norley S, Lipp M, Walther W, Pezzutto A, Westermann J.

Oncoimmunology. 2012 Dec 1;1(9):1537-1545.

32.

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.

Scholz CW, Pinto A, Linkesch W, Lindén O, Viardot A, Keller U, Hess G, Lastoria S, Lerch K, Frigeri F, Arcamone M, Stroux A, Frericks B, Pott C, Pezzutto A.

J Clin Oncol. 2013 Jan 20;31(3):308-13. doi: 10.1200/JCO.2011.41.1553. Epub 2012 Dec 10.

PMID:
23233718
33.

Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer.

Jehn CF, Flath B, Strux A, Krebs M, Possinger K, Pezzutto A, Lüftner D.

Breast Cancer Res Treat. 2012 Dec;136(3):789-94. doi: 10.1007/s10549-012-2311-2. Epub 2012 Nov 3.

PMID:
23124416
34.

CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.

Nguyen-Hoai T, Hohn O, Vu MD, Baldenhofer G, Sayed Ahmed MS, Dörken B, Norley S, Lipp M, Pezzutto A, Westermann J.

Cancer Gene Ther. 2012 Dec;19(12):880-7. doi: 10.1038/cgt.2012.78. Epub 2012 Oct 26.

PMID:
23099886
35.

Detection of circulating tumor-associated antigen depends on the domains recognized by the monoclonal antibodies used: N-terminal trimmed EpCAM-levels are much higher than untrimmed forms.

Schmetzer O, Moldenhauer G, Nicolaou A, Schlag P, Riesenberg R, Pezzutto A.

Immunol Lett. 2012 Apr 30;143(2):184-92. doi: 10.1016/j.imlet.2012.02.004. Epub 2012 Feb 22.

PMID:
22387297
36.

CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model.

Nguyen-Hoai T, Baldenhofer G, Ahmed MS, Pham-Duc M, Gries M, Lipp M, Dörken B, Pezzutto A, Westermann J.

J Gene Med. 2012 Feb;14(2):128-37. doi: 10.1002/jgm.1651.

PMID:
22228591
37.

Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.

Flörcken A, Takvorian A, Van Lessen A, Singh A, Hopfenmüller W, Dörken B, Pezzutto A, Westermann J.

Anticancer Drugs. 2012 Mar;23(3):298-302. doi: 10.1097/CAD.0b013e32834ee2b1.

PMID:
22156795
38.

CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.

Nguyen-Hoai T, Baldenhofer G, Sayed Ahmed MS, Pham-Duc M, Vu MD, Lipp M, Dörken B, Pezzutto A, Westermann J.

Cancer Gene Ther. 2012 Jan;19(1):69-76. doi: 10.1038/cgt.2011.69. Epub 2011 Oct 14.

PMID:
21997231
39.

Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells.

Waiczies H, Lepore S, Janitzek N, Hagen U, Seifert F, Ittermann B, Purfürst B, Pezzutto A, Paul F, Niendorf T, Waiczies S.

PLoS One. 2011;6(7):e21981. doi: 10.1371/journal.pone.0021981. Epub 2011 Jul 19.

40.

Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study.

Westermann J, Flörcken A, Willimsky G, van Lessen A, Kopp J, Takvorian A, Jöhrens K, Lukowsky A, Schönemann C, Sawitzki B, Pohla H, Frank R, Dörken B, Schendel DJ, Blankenstein T, Pezzutto A.

Gene Ther. 2011 Apr;18(4):354-63. doi: 10.1038/gt.2010.143. Epub 2010 Nov 11.

PMID:
21068778
41.

Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system.

Foti C, Florean C, Pezzutto A, Roncaglia P, Tomasella A, Gustincich S, Brancolini C.

Mol Cancer Ther. 2009 Nov;8(11):3140-50. doi: 10.1158/1535-7163.MCT-09-0431. Epub 2009 Nov 3.

42.

Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.

Buchner A, Pohla H, Willimsky G, Frankenberger B, Frank R, Baur-Melnyk A, Siebels M, Stief CG, Hofstetter A, Kopp J, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ.

Hum Gene Ther. 2010 Mar;21(3):285-97. doi: 10.1089/hum.2008.192.

PMID:
19788391
43.
44.

Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.

Weisel KC, Weidmann E, Anagnostopoulos I, Kanz L, Pezzutto A, Subklewe M.

Int J Hematol. 2008 Nov;88(4):434-440. doi: 10.1007/s12185-008-0176-2. Epub 2008 Oct 7.

PMID:
18839273
45.

Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report.

Sturm I, Oertel J, Oertel S, Westermann J, Pezzutto A.

J Med Case Rep. 2008 Aug 14;2:275. doi: 10.1186/1752-1947-2-275.

46.

Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis - a pilot study.

Hildebrandt B, Müller C, Pezzutto A, Daniel P, Dörken B, Scholz C.

BMC Cancer. 2007 Oct 3;7:185.

47.

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M, Tilly H, Raemaekers J, van 't Veer MB, Milpied N, Cartron G, Pezzutto A, Spencer A, Reyes F, Dreyling M.

Ann Oncol. 2008 Feb;19(2):247-53. Epub 2007 Sep 28.

PMID:
17906297
48.

Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.

Westermann J, Kopp J, van Lessen A, Hecker AC, Baskaynak G, le Coutre P, Döhner K, Döhner H, Dörken B, Pezzutto A.

Br J Haematol. 2007 May;137(4):297-306. Epub 2007 Apr 4.

PMID:
17408402
49.

CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity.

Westermann J, Nguyen-Hoai T, Baldenhofer G, Höpken UE, Lipp M, Dörken B, Pezzutto A.

Cancer Gene Ther. 2007 Jun;14(6):523-32. Epub 2007 Mar 23.

PMID:
17384577
50.

Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.

Subklewe M, Sebelin-Wulf K, Beier C, Lietz A, Mathas S, Dörken B, Pezzutto A.

Hum Immunol. 2007 Mar;68(3):147-55. Epub 2007 Jan 4.

PMID:
17349869

Supplemental Content

Loading ...
Support Center